This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AKER Akers Biosciences (AKER) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock About Akers Biosciences Stock (NASDAQ:AKER) 30 days 90 days 365 days Advanced Chart Get Akers Biosciences alerts:Sign Up Key Stats Today's Range$0.08▼$0.0950-Day Range$2.47▼$4.5952-Week Range$1.65▼$6.97Volume306.18 million shsAverage Volume769,876 shsMarket Capitalization$1.50 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Akers Biosciences, Inc. focuses on the development of a vaccine candidate against SARS-CoV-2, a coronavirus causing a pandemic. It has a collaboration agreement with Premas Biotech PVT Ltd. The company was incorporated in 1989 and is headquartered in New York, New York. Read More Receive AKER Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akers Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AKER Stock News HeadlinesNewly-signed running back Cam Akers has already changed his jersey numberJune 30, 2025 | msn.comClinton native Cam Akers signs with New Orleans SaintsJune 17, 2025 | msn.comA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boom. For retirees, that could mean a way to generate reliable monthly income—without the outdated 4% withdrawal rule, risky trading, or high-fee annuities. If you’re ready to stop worrying about money running out and start enjoying the freedom to cover expenses, treat loved ones, and live life on your terms, this may be exactly what you’ve been waiting for.August 28 at 2:00 AM | Investors Alley (Ad)Former Houston Texans RB Cam Akers signs one-year deal with the SaintsJune 14, 2025 | msn.comNew Orleans Saints set to sign RB Cam Akers, but Reddit plots his return to Minnesota VikingsJune 14, 2025 | msn.comSaints sign Cam Akers, adding more competition to their backfieldJune 14, 2025 | msn.comCam Akers Not Worth A Look In Week 10November 10, 2024 | msn.comCam Akers Totals 14 Touches With Aaron Jones Tending To InjuryNovember 10, 2024 | msn.comSee More Headlines AKER Stock Analysis - Frequently Asked Questions How were Akers Biosciences' earnings last quarter? Akers Biosciences, Inc. (NASDAQ:AKER) announced its quarterly earnings data on Thursday, November, 15th. The medical instruments supplier reported ($0.26) earnings per share (EPS) for the quarter. The medical instruments supplier earned $0.56 million during the quarter. What other stocks do shareholders of Akers Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Akers Biosciences investors own include Sorrento Therapeutics (SRNE), Aytu BioPharma (AYTU), ImmunoGen (IMGN), AVEO Pharmaceuticals (AVEO), Advanced Micro Devices (AMD), Vaxart (VXRT) and Neovasc (NVCN). Company Calendar Last Earnings11/15/2018Today8/28/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic Substances Sub-IndustryN/A Current SymbolNASDAQ:AKER CIK1321834 Webwww.akersbio.com Phone856 848 8698FaxN/AEmployees4Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.89 million Net MarginsN/A Pretax MarginN/A Return on Equity-87.42% Return on Assets-73.31% Debt Debt-to-Equity RatioN/A Current Ratio9.22 Quick Ratio9.22 Sales & Book Value Annual Sales$1.58 million Price / Sales0.95 Cash FlowN/A Price / Cash FlowN/A Book Value$5.38 per share Price / Book0.02Miscellaneous Outstanding Shares16,653,000Free FloatN/AMarket Cap$1.50 million OptionableNot Optionable Beta0.30 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:AKER) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump's "Big Beautiful Bill" hides ugly truthWashington’s new “Big Beautiful Bill” promises tax breaks… but the fine print tells a different story: trillio...Defi Master | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akers Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akers Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access